ACCESS Newswire

Promore Pharma

Share
Nomination Committee Appointed for the Annual General Meeting 2022 in Promore Pharma

STOCKHOLM, SE / ACCESSWIRE / November 16, 2021 / Promore Pharma (STO:PROMO) (FRA:8T0)

Promore Pharma AB (publ) today announced the composition of the Nomination Committee for the Annual General Meeting 2022, which will be held on Tuesday 17 May 2022. The Nomination Committee shall, according to decided principles for the appointment of the Nomination Committee, consist of the Chairman of the Board and representatives for the three largest shareholders in the company.

The main task of the Nomination Committee is to submit proposals for Chairman of the Board and other members of the Board, remuneration for Board work, the election and remuneration of auditors. The Nomination Committee shall be composed of the Chairman of the Board and members appointed by the three largest shareholders in the company based on ownership of the Company as per the end of September 2021.

Accordingly, the following committee members have been appointed:

  • Göran Pettersson, Chairman of the Board
  • David Sundin, representing Corespring New Technology AB (former Midroc New Technology)
  • Henric Rahm, representing PharmaResearch Co. Ltd
  • Hans-Peter Ostler, representing a co-registered group of shareholders, with an ownership equivalent to 8.2% of the company

The Nomination Committee's proposals will be presented in the Notice to the AGM 2022 and on the company web site, www.promorepharma.com. Shareholders desiring to submit comments or proposals to the nomination committee can send them via email to info@promorepharma.com.

For additional information, please contact

Jonas Ekblom, CEO
Phone: [+46] 736 777 540
E-mail: jonas.ekblom@promorepharma.com

Erik Magnusson, CFO
Phone: [+46] 708 565 245
E-mail: erik.magnusson@promorepharma.com

Promore Pharmas Certified Adviser is Erik Penser Bank
Tel: [+46] 8-463 83 00
E-mail: certifiedadviser@penser.se

Promore Pharma in brief

Promore Pharma is a biopharmaceutical company specialized in the development of therapeutic peptides. The company's aim is to develop first-in-category pharmaceuticals for indications with high unmet medical needs, where very few efficacious prescription pharmaceuticals are available. Promore Pharma's two projects are undergoing clinical development and have a very strong safety profile since the products are based on endogeneous substances that are administered locally. The leading project, ensereptide (PXL01), that will be used for prevention of post-surgical scarring, is being prepared for a clinical phase II-trial if the peptide can prevent the formation of unesthetical scars on the skin. Ropocamptide (LL-37) has recently been evaluated in a clinical phase IIb study with positive results in patients with venous leg ulcers (VLUs). The product candidates can also be deployed for other indications, such as preventing unfavorable tissue attachments (adhesions) after different kinds of surgical procedures and treatment of diabetic foot ulcers. The company is listed on Nasdaq First North Growth Market.

SOURCE: Promore Pharma



View source version on accesswire.com:
https://www.accesswire.com/673114/Nomination-Committee-Appointed-for-the-Annual-General-Meeting-2022-in-Promore-Pharma

To view this piece of content from www.accesswire.com, please give your consent at the top of this page.

About ACCESS Newswire

DK

Subscribe to releases from ACCESS Newswire

Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from ACCESS Newswire

Champions Oncology Launches Radiopharmaceutical Services Platform, Expands Isotope License, and Screens More Than 30 PDX Models8.7.2025 14:30:00 CEST | Press release

Expanded offering delivers integrated radiopharmaceutical studies using clinically relevant isotopes and highly characterized PDX tumor models HACKENSACK, NJ / ACCESS Newswire / July 8, 2025 / Champions Oncology (NASDAQ:CSBR) a leading translational oncology research organization, today announced the full commercial launch of its radiopharmaceutical services platform. This milestone follows the expansion of the company's radioactive materials license, the completion of the radiochemistry infrastructure, and the successful screening of more than thirty PDX models in collaboration with pharmaceutical and biotech partners. Champions now offers fully integrated radiopharmaceutical workflows combining in vitro, ex-vivo biodistribution, and therapeutic efficacy studies across a wide range of isotopes. The company's platform is uniquely differentiated by its extensive bank of patient-derived xenograft (PDX) tumor models, enabling drug developers to evaluate radiolabeled agents in clinically r

Karbon-X Becomes Official Name Sponsor of BK Dukes Basketball Team8.7.2025 09:00:00 CEST | Press release

CALGARY, AB / ACCESS Newswire / July 8, 2025 / Karbon-X Corp. (OTCQX:KARX), a vertically integrated climate solutions company, has signed a multi-year agreement to become the official name sponsor of BK Dukes, one of Austria's top professional basketball teams. Effective immediately, the team will compete as the BK Karbon-X Dukes. This partnership brings together two high-performance organizations committed to community, innovation, and progress chon and off the court. Fresh off their 2024-2025 Austrian Cup Title win, the BK Dukes are working with Karbon-X to integrate measurable sustainability initiatives throughout the organization. This includes annual emissions reporting, offsetting all team and venue Scope 1, 2, and 3 emissions, and incorporating an emissions offset fee into every ticket purchase to address fan-related impacts. Together, they are building a model of leadership that extends far beyond the scoreboard. "This partnership represents what climate action should look like

Polaris Renewable Energy Announces Q1 2025 Investor Call Details7.7.2025 22:10:00 CEST | Press release

TORONTO, ON / ACCESS Newswire / July 7, 2025 / Polaris Renewable Energy Inc. (TSX:PIF) ("Polaris" or the "Company") is pleased to announce it will be holding its Earnings Conference Call and Webcast to report its Q2 2025 Earnings Results on Thursday, July 31st, 2025, at 10:00 am EST. To listen to the call, please dial Toll Free 888-506-0062 or International Toll-Free Number 973-528-0011 entry code 108489. or URL: https://www.webcaster4.com/Webcast/Page/2773/51833 A digital recording of the earnings call will be available for replay two hours after the call's completion. Replay Call Information: Toronto: 1 877-481-4010, Passcode: 51833 International (toll-free): 1 919-882-2331, Passcode: 51833 Encore Replay Expiration Date: August 14, 2025 About Polaris Renewable Energy Inc. Polaris Renewable Energy Inc. is a Canadian publicly traded company engaged in the acquisition, development, and operation of renewable energy projects in Latin America and the Caribbean. We are a high-performing an

Innodata to Report Second Quarter 2025 Results7.7.2025 14:30:00 CEST | Press release

NEW YORK, NY / ACCESS Newswire / July 7, 2025 / INNODATA INC. (Nasdaq:INOD) today announced that it will report Second Quarter 2025 results after the market closes on Thursday, July 31, 2025. A news release will be available in both the News and Investor Relations sections of the Innodata website, www.innodata.com Innodata has scheduled an investor conference call for 5:00 PM Eastern time on that same day. The call-in numbers for the conference call are: (+1) 800 549 8228 North America (+1) 289 819 1520 International Participant Access Code 18067# Investors are also invited to access a live Webcast of the conference call at the Investor Relations section of Innodata's website at https://investor.innodata.com/events-and-presentations/. Please note that the Webcast feature will be in listen-only mode. Call-in replay will be available for seven days following the conference call, and Webcast replay will be available for 30 days following the conference call, at the Investor Relations sect

GoodData Launches AI for Self-Hosted Analytics: Powerful, Proven, Private7.7.2025 14:30:00 CEST | Press release

GoodData AI capabilities, including AI Assistant and Smart Search, now available for self-hosted deployment. Keep your data private, compliant, and AI-fuelled. SAN FRANCISCO, CALIFORNIA / ACCESS Newswire / July 7, 2025 / GoodData, the AI-native analytics platform, today announced GoodData AI is now available for self-hosted deployment. Enterprises can now run GoodData AI, including AI Assistant and Smart Search, entirely within their own infrastructure - on-premises or in a private cloud - with zero third-party data exposure. With this launch, GoodData delivers the full promise of AI-driven analytics while honoring the strict privacy, compliance, and control requirements of modern enterprises. Self-hosting gives organizations total ownership of their analytics workflows, from natural language queries to insight generation, all within their secure perimeter. "Enterprises shouldn't have to choose between innovation and control. With self-hosted GoodData AI, we're giving our customers the

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye